

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Assistant Commissioner for Patents
Washington, D.C. 20231

On January 12, 2000

TOWNSEND and TOWNSEND and CREW LLP

By: Jennifer K. Hardi

Box Sea / Gam 1635
PATENT
Attorney Docket No.: 015280-377000US
Client Reference No.: E-286-98/0

RECEIVED

JAN 24 2000

#6/A
Plunkett
2-1-00

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

BRENNEMAN *et al.*

Application No.: 09/267,511

Filed: March 12, 1999

For: PREVENTION OF FETAL
ALCOHOL SYNDROME AND
NEURONAL CELL DEATH WITH
ADNF POLYPEPTIDES

Examiner: Zara, Jane

Art Unit: 1635

COMMUNICATION UNDER

37 C.F.R. §§ 1.821-1.825

AND

AMENDMENT

Box SEQUENCE
Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:


In response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, 37 C.F.R. §§ 1.821-1.825, that accompanied the Office Communication mailed December 14, 1999, Applicants submit herewith the required paper copy and computer readable copy of the Sequence Listing. Please amend the specification in adherence with 37 C.F.R. §§ 1.821-1.825 as follows.

IN THE SPECIFICATION:

On page 5, line 8, replace "NAPVSIPQ+alcohol (25),
NAPVSIPQ+NAPVSIPQ+alcohol" with --NAPVSIPQ (SEQ ID NO:2) + alcohol (25),
NAPVSIPQ (SEQ ID NO:2) + NAPVSIPQ (SEQ ID NO:2) + alcohol--

RECEIVED

JAN 20 2000



AL